



**HAL**  
open science

## Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

Capucine Baldini, E. Charton, E. Schultz, L. Auroy, A. Italiano, M. Robert, E. Coquan, Nicolas Isambert, P. Moreau, S. Le Gouill, et al.

### ► To cite this version:

Capucine Baldini, E. Charton, E. Schultz, L. Auroy, A. Italiano, et al.. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. *ESMO Open*, 2022, European Society for Medical Oncology, 7, pp.100468. 10.1016/j.esmoop.2022.100468 . hal-04567217

**HAL Id: hal-04567217**

**<https://hal.univ-lille.fr/hal-04567217>**

Submitted on 3 May 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

ORIGINAL RESEARCH

## Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

C. Baldini<sup>1,2\*</sup>, E. Charton<sup>3</sup>, E. Schultz<sup>4,5</sup>, L. Auroy<sup>6</sup>, A. Italiano<sup>7,8</sup>, M. Robert<sup>9</sup>, E. Coquan<sup>10</sup>, N. Isambert<sup>11</sup>, P. Moreau<sup>12</sup>, S. Le Gouill<sup>13</sup>, C. Le Tourneau<sup>14</sup>, Z. Ghrieb<sup>15</sup>, J. J. Kiladjian<sup>16</sup>, J. P. Delord<sup>16</sup>, C. Gomez Roca<sup>16</sup>, N. Vey<sup>17</sup>, F. Barlesi<sup>18,19</sup>, T. Lesimple<sup>20</sup>, N. Penel<sup>21</sup>, J. C. Soria<sup>19</sup>, C. Massard<sup>1</sup> & S. Besle<sup>1,2,22</sup>

<sup>1</sup>Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif; <sup>2</sup>Laboratory for Immunomonitoring in Oncology (LIO), University Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif; <sup>3</sup>Human and Social Sciences Department, Centre Léon Bérard, Lyon; <sup>4</sup>CEPED (UMR 196), Université de Paris, IRD, Paris; <sup>5</sup>SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, CANBIOS Team (Équipe Labellisée LIGUE 2019), Aix-Marseille University, INSERM, IRD, Marseille; <sup>6</sup>Université Grenoble Alpes, CNRS, Sciences Po Grenoble, Pacte, Grenoble; <sup>7</sup>Institut Bergonié, Early Phase Trials and Sarcoma Units, Bordeaux; <sup>8</sup>University of Bordeaux, Bordeaux; <sup>9</sup>Institut de Cancérologie de l'Ouest, Medical Oncology Department, Saint-Herblain; <sup>10</sup>François Baclesse Cancer Center, Department of Oncology, Caen; <sup>11</sup>Département d'Innovations Thérapeutiques/recherche Translationnelle en Oncologie et Hématologie (DITTOH), INSERM U1084, CHU de Poitiers, Poitiers; <sup>12</sup>Centre GF Leclerc, Medical Oncology Department, Dijon; <sup>13</sup>Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes; <sup>14</sup>Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, Paris & Saint-Cloud; <sup>15</sup>APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris; <sup>16</sup>Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-OncoPole), Toulouse; <sup>17</sup>Aix-Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, Hematology Department, CRCM, Marseille; <sup>18</sup>Aix Marseille University, CNRS, INSERM, CRCM, APHM, Marseille Early Phases Cancer Center CLIP<sup>2</sup>, Marseille; <sup>19</sup>Gustave Roussy, Université Paris-Saclay, Villejuif; <sup>20</sup>Clinical Research Department, CLIP<sup>2</sup> and ARPEGO Network, Rennes; <sup>21</sup>CLIP<sup>2</sup> Lille, Centre Oscar Lambret, Lille and Lille University, Lille; <sup>22</sup>Lyon 1 University, EA4129, Lyon, France



Available online 6 May 2022

**Background:** Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most cancers increases with age, new drugs should also be evaluated in older patients to assess their safety and efficacy. The EGALICAN-2 study was primarily designed to identify social and/or regional inequalities regarding access to ECT. We focused on the factors of inequalities in access to ECT in older patients.

**Patients and methods:** During a 1-year period (2015-2016), a survey was conducted in 11 early-phase units certified by the French National Cancer Institute.

**Results:** A total of 1319 patients were included in the analyses: 1086 patients (82.3%) were <70 years and 233 patients (17.7%) were >70 years. The most common tumor types at referral in older patients were gastrointestinal (19.3%), hematological (19.3%), and thoracic tumors (18.0%). Most patients referred to the phase I unit had signed informed consent and the rate was similar across age (92.7% in younger patients versus 90.6% in older patients;  $P = 0.266$ ). The rate of screening failure was also similar across age (28.5% in younger patients versus 24.3% in older patients;  $P = 0.219$ ). Finally, in older patients, univariate analyses showed that initial care received in the hospital having a phase I unit was statistically associated with first study drug administration (odds ratio 0.49, 90% confidence interval 0.27-0.88;  $P = 0.045$ ).

**Conclusions:** Older patients are underrepresented in early clinical trials with 17.7% of patients aged  $\geq 70$  years compared with the number of new cases of cancer in France (50%). However, when invited to participate, older patients were prone to sign informed consent.

**Key words:** early-phase clinical trials, cancer, older patients, enrollment, access

### INTRODUCTION

Cancer is the second most common cause of death in older adults after heart disease.<sup>1</sup> The death rate from cancer in

the United States in adults aged  $\geq 85$  years was expected to be  $\sim 103\,250$  in 2019 (49 040 male and 54 210 female deaths), accounting for 17% of all cancer deaths.<sup>1</sup> The number of new cancer cases is expected to rise rapidly over the next years due to the aging and growth of the population.<sup>2</sup> However, older patients remain underrepresented in clinical trials despite published recommendations from the Food and Drug Administration (FDA) as early as 1989.<sup>3</sup> In March 2020, new guidelines have been implemented with explicit recommendations for including

\*Correspondence to: Dr Capucine Baldini, 114 rue Edouard Vaillant, 94800 Villejuif, France. Tel: +33-1-42-11-42-11; Fax: +33-1-42-11-64-44  
E-mail: [capucine.baldini@gustaveroussy.fr](mailto:capucine.baldini@gustaveroussy.fr) (C. Baldini).

2059-7029/© 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

an adequate representation of older adults in cancer clinical trials.<sup>4</sup> They highlight the importance of enrolling patients, especially those aged  $\geq 75$ , in early-phase clinical trials, and evaluate potential drug interactions early in the development process, to benefit older adults when designing trials and recruitment strategies; collecting data specific to older adults during trials and including older adults in postmarketing studies are also of major importance.<sup>4</sup> In France, the identification and support of research centers specialized in early-phase clinical trials (ECT) were part of the 2009-2013 Cancer Plan. This initiative set up a powerful network over the French territory to ensure access to ECT regardless of the patient residence. The EGALICAN-2 study was primarily designed to identify social and/or regional inequalities regarding access to ECT. In this study, we focused on the access to ECT in the aging population.

## METHODS

### EGALICAN-2 survey

EGALICAN-2 is a national multicenter prospective study designed to assess the equality of access to ECT. The study was approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIRS number: 13.660) and by the French Data Protection Authority (CNIL number: DR-2014-331). During a 1-year period (2015-2016), a survey was conducted in 11 early-phase units certified by the French National Cancer Institute. All patients referred to the hospital were able to give consent to participate in the study and fulfill a survey developed by a sociologist team. The survey was divided in two parts: the first dedicated to the patient for personal information, the second, dedicated to the medical staff for patient medical information. We collected socioeconomical information (e.g. age, sex, place of birth, level of education, and profession), medical information (e.g. cancer site, type of treatment, and grade), and ECT information. The geographic context of the patients' place of residence was considered using the French Deprivation Index<sup>5</sup> as well as the patients' travel time by car to the inclusion center. The higher the French Deprivation Index, the higher deprived the patient's place of residence. The geographic context was not considered for patients from French overseas territories. The population-based cancer incidence estimates for the year 2020 were obtained for all cancers, in patients aged  $\geq 70$  years in France using the GLOBOCAN database produced by the International Agency for Research on Cancer (gco.iarc.fr).<sup>6</sup>

### Statistical analysis

Patients were divided into two categories according to age: an older group ( $\geq 70$  years) and a younger group ( $< 70$  years). Qualitative and quantitative variables were described by their absolute and relative frequencies and mean (standard deviation) and median (minimum-maximum), respectively, and then compared using the  $\chi^2$  or

Fisher's exact test and the Mann-Whitney nonparametric test, respectively. The percentage of older patients with cancer in the EGALICAN-2 study and the percentage of older patients with cancer in France were compared using a Z-test. Univariate logistic regression models were performed in older patients to explore factors associated with the first administration of the experimental treatment (cycle 1, day 1) and to estimate odds ratios (ORs) and 90% confidence intervals (CIs). All analyses were performed with SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA) and Python (version 3.8.5).

## RESULTS

### Patient characteristics at referral

Between 2015 and 2016, a total of 1355 patients referred from 11 early-phase units in France participated in the study. Among them, 1319 patients (97.3%) had the information about age. Most patients referred in ECT were  $< 70$  years ( $n = 1086$ , 82.3%), and 233 patients (17.7%) were  $> 70$  years (Figure 1). The median age was 58 (range 17-70) years in the younger population and 74 (range 70-97) years in the older population. Significantly more female patients were referred among younger patients (55.5%) and male patients among older patients (52.4%;  $P = 0.028$ ; Table 1). Most patients were treated for solid tumors but the proportion of patients treated for hematological malignancies was higher in older patients (19.3% versus 8.7%). Patients had predominantly metastatic cancer ( $n = 797$ , 87.9%; Table 2). There was no other difference when looking specifically in the population of patients aged  $\geq 80$  years (Supplementary Table S1, available at <https://doi.org/10.1016/j.esmooop.2022.100468>).

Considering the estimated number of new cases in 2020, all cancers, both sexes, with an age of  $\geq 20$  years in France (465 125 cases), and the estimated number of new cases with an age of  $\geq 70$  years (232 294 cases), the number of new cases of cancer in older patients represented 50% of all cases in France. The difference between the rate of enrollment in our study (17.7%) compared with 50% (number of new cases considered as reference) was statistically significant with ( $P < 0.001$ ).

### Signature of informed consent and first administration of the experimental treatment

Most patients that were referred to the phase I unit had signed informed consent. The rate was similar across age (92.7% in younger patients versus 90.6% in older patients;  $P = 0.266$ ). In the older population, reasons for absence of signature were patient's refusal to participate in the study (28.6%), exclusion biological criteria (38.1%), no slot available (23.8%), and others (9.5%).

The rate of screening failure was 28.5% in younger patients versus 24.3% in older patients ( $P = 0.219$ ; Table 2). Reasons for screening failure are described for the whole population in Supplementary Table S2, available at <https://doi.org/10.1016/j.esmooop.2022.100468>. The main reasons




Figure 1. Flowchart of patients included in the analyses.

were as follows: protocol-required tumor did not meet eligibility criteria (41.2%), development of an interval medical issue that precluded proceeding with study participation (12.2%), patient declined participation after signed consent (5.4%), discovery of an exclusionary preexisting medical condition (5.1%), out-of-protocol-specified range for chemical laboratory results (4.8%), imaging/radiology issue (3.7%), and presence of exclusionary brain metastasis (1.7%).

### Geographic/social access to innovative drugs

Older patients who were referred to the phase I unit predominantly lived with one person (71.2%) compared with younger patients (50.4%;  $P < 0.001$ ). They lived closer to the hospital compared with their younger counterparts [median 66 minutes by car (range 0-539) for patients older than 70 years versus 81 minutes by car (range 0-1155) for patients younger than 70 years;  $P = 0.006$ ; Table 1]. The geographical distribution of referral of older patients in France is described on Figure 2.

Older patients had a significantly lower education level (<high-school degree) as compared with younger patients (60.4% versus 46.9%;  $P < 0.001$ ; Table 1). There were more craftsmen/retailers/business leaders and executives/white-collar workers in the older population compared with younger patients (18.5% versus 10.9% and 28.7% versus 23.6% respectively;  $P = 0.016$ ; Supplementary Figure S1, available at <https://doi.org/10.1016/j.esmooop.2022.100468>). There was no difference in terms of French Deprivation Index ( $P = 0.167$ ). Other social characteristics are detailed in Table 1.

### Treatment characteristics

Targeted therapies and immunotherapy agents were evaluated in 40.1% and 30.6% of patients <70 years and 39.2% and 25.6% of patients >70 years, respectively ( $P = 0.001$ ). Epigenetic drugs were used in 10.1% of older patients and in 6.5% of younger patients in relation to the higher number of older patients treated for hematological malignancies. Finally, hormonotherapy and chemotherapy were evaluated in 0.7% and 1.8% of younger patients and 4.8% and 3.1% of older patients (Supplementary Figure S2, available at <https://doi.org/10.1016/j.esmooop.2022.100468>). Older patients received combination therapy in 47.5% of cases compared with 51.4% in younger patients ( $P = 0.323$ ; Table 2).

### Factors associated with first study drug administration in the older population

The univariate analyses showed that initial care received in the hospital having a phase I unit was statistically associated with the administration of the treatment (OR 0.49, 90% CI 0.27-0.88;  $P = 0.045$ ). No other factor was significantly associated with first study drug administration (Table 3).

### DISCUSSION

To our knowledge, this is the first study to report a national experience of access to innovative drugs for older patients. The expansion of early clinical trials and geriatric oncology have been a priority across all French Cancer plans since 2006 and 2009. However, older patients remain underrepresented in clinical trials, and especially in early-phase clinical trials, even though they represent 42% of the overall

Characteristics	<70 years (n = 1086), n (%)	≥70 years (n = 233), n (%)	P value
<i>Social characteristics</i>			
<b>Age at the date of presentation of the trial (in years)</b>			
Mean (standard deviation)	55 (11.3)	75 (4.1)	
Median (range)	58 (17 to 70)	74 (70 to 97)	
<b>Sex</b> 0.028			
Female	603 (55.5)	111 (47.6)	
Male	483 (44.5)	122 (52.4)	
<b>Place of residence outside France</b> >0.99 <sup>a</sup>			
No	1081 (99.5)	232 (99.6)	
Yes	5 (0.5)	1 (0.4)	
<b>Place of birth</b> 0.718			
Continental France	955 (88.3)	203 (87.5)	
Other	126 (11.7)	29 (12.5)	
<b>Number of people at home (including the patient)</b> <0.001			
1 person	159 (14.8)	53 (22.7)	
2 people	543 (50.4)	166 (71.2)	
≥3 people	375 (34.8)	14 (6.0)	
<b>Private insurance</b> 0.164			
No	44 (4.1)	5 (2.2)	
Yes	1021 (95.9)	223 (97.8)	
<b>Education level</b> <0.001			
<High-school degree	498 (46.9)	137 (60.4)	
=High-school degree	175 (16.5)	36 (15.9)	
>High-school degree	388 (36.6)	54 (23.8)	
<b>Employment status</b> <0.001			
Active <sup>b</sup>	307 (30.4)	0 (0.0)	
Inactive <sup>c</sup>	704 (69.6)	231 (100.0)	
<b>Health sector profession</b> 0.650			
No	947 (91.0)	194 (91.9)	
Yes	94 (9.0)	17 (8.1)	
<i>Geographic characteristics</i>			
<b>French Deprivation Index</b> 0.167 <sup>d</sup>			
Mean (standard deviation)	-0.3 (1.6)	-0.4 (1.6)	
Median (range)	-0.2 (-6 to 6)	-0.4 (-6 to 5)	
<b>Journey time to the inclusion center (in minutes)</b> 0.006 <sup>b</sup>			
Mean (standard deviation)	104 (101.1)	86 (82.9)	
Median (range)	81 (0 to 1155)	66 (0 to 539)	

A chi-square test was used unless indicated otherwise.

<sup>a</sup>Fisher's exact test.

<sup>b</sup>Full-time job and part-time job.

<sup>c</sup>Looking for employment, retired, at home, disability, training, medical leave, cessation of self-employed activity, no profession, and student.

<sup>d</sup>Mann-Whitney nonparametric test.

cancer population.<sup>7-11</sup> In our analysis, they represented 17.7% of the total number of patients enrolled, whereas in France they represent 50% of new cases of cancer (gco.iarc.fr). A recent study found that the median age of patients, in more than 300 randomized trials involving four common cancers, was 6.5 years younger than that of the general population with the same diagnoses.<sup>11</sup> Many potential barriers have been identified related to patient, physician, trial/protocol, and logistics.<sup>12</sup> One of the first potential barrier is age alone. In the last years there has been a tremendous effort to avoid age as an exclusion criterion. In a recent study, Ludmir et al.<sup>11</sup> found that upper age restriction criterion was identified in 10.1% of 742 phase


Characteristics	<70 years (n = 1086), n (%)	≥70 years (n = 233), n (%)	P value
<b>Cancer site<sup>a</sup></b>			
Brain	44 (4.1)	4 (1.7)	
Breast	184 (17.0)	22 (9.4)	
Endocrine	17 (1.6)	2 (0.9)	
Gastrointestinal	235 (21.7)	45 (19.3)	
Gynecological	117 (10.8)	25 (10.7)	
Head and neck	79 (7.3)	9 (3.9)	
Respiratory system	148 (13.7)	42 (18.0)	
Skin	16 (1.5)	3 (1.3)	
Sarcoma	54 (5.0)	1 (0.4)	
Urological	88 (8.1)	35 (15.0)	
Blood	94 (8.7)	45 (19.3)	
Unknown	7 (0.6)	1 (0.4)	
<b>Drugs combination</b> 0.323			
No	430 (48.6)	104 (52.5)	
Yes	454 (51.4)	94 (47.5)	
<b>Metastatic cancer</b> 0.744			
No	93 (12.3)	17 (11.3)	
Yes	664 (87.7)	133 (88.7)	
<b>Initial care received in another hospital without a phase I unit</b> 0.183			
No	366 (34.2)	89 (38.9)	
Yes	703 (65.8)	140 (61.1)	
<b>Signature of consent</b> 0.266			
No	79 (7.3)	22 (9.4)	
Yes	1003 (92.7)	211 (90.6)	
<b>Reason for nonsignature of consent (n = 101)</b> 0.618 <sup>b</sup>			
Biological criteria	34 (53.1)	8 (38.1)	
No place available	10 (15.6)	5 (23.8)	
Patient	14 (21.9)	6 (28.6)	
Other	6 (9.4)	2 (9.5)	
<b>Administration of the experimental treatment (cycle 1 day 1, n = 1214)</b> 0.219			
No	267 (28.5)	49 (24.3)	
Yes	669 (71.5)	153 (75.7)	

A chi-square test was used unless indicated otherwise.

<sup>a</sup>Total percentages may exceed 100 since several responses were possible.

<sup>b</sup>Fisher's exact test.

III randomized clinical trials. Phase I trials were not included in the analysis. Alternate eligibility criteria that can exclude older patients are related to functional status, organ function, comorbidity, and comedication that are frequent in the older population. These criteria may vary according to the type of compound tested (e.g. less restrictive with immune checkpoint blockers or immunotherapy compared with chemotherapy clinical trials). However, these are often included systematically in protocols with few scientific background.<sup>13,14</sup> American Society of Clinical Oncology (ASCO), Friends of Cancer Research, and the FDA published suggestions to revise some of these criteria to avoid too many restrictive criteria and improve patient accrual in clinical trials.<sup>4,15,16</sup> The European Medicines Agency (EMA) also issued guidance on geriatric medicine strategies in 2011 to ensure that the needs of older people are taken into account in the development and evaluation of new medicines.<sup>17,18</sup> Most of the data available in older patients are derived from a subgroup analyses of phase III registration



**Figure 2.** Patient referral in early-phase clinical trials per French department according to age.

trials, making it difficult to extrapolate. Moreover, the older population is very heterogeneous and chronological age itself does not reflect physiological age assessed by comprehensive geriatric assessment.<sup>19</sup> Comprehensive geriatric assessment explores different areas including functional status, mobility, cognition, emotional status, nutritional status, comorbidities, polypharmacy, and social support. It helps guiding treatment decision and implementing interventions to improve patients outcome.<sup>20-23</sup> Its use is recommended by international societies.<sup>24,25</sup> Geriatric assessment is not yet implemented in clinical trials despite the critical need to provide data to better describe the older

population enrolled in clinical trials. To allow both a minimal geriatric description of the older patients with cancer and a standardization of geriatric data, some tools have been developed such as the Geriatric Core Dataset (G-CODE) specifically designed for clinical trials.<sup>26</sup> It consists of two social questions, two autonomy scales (activities of daily living and 4-item instrumental activities of daily living), a mobility scale (Timed Get Up and Go Test), two nutrition items (weight loss and body mass index), a cognitive scale (Mini-Cog), a scale assessing the depressive mood (Mini-Geriatric Depression Scale), and a comorbidity overview (updated Charlson Comorbidity Index).<sup>26</sup>

**Table 3.** Results of the univariate logistic regression of factors associated with the administration of the experimental treatment in patients older than 70 years

Factors	Administration of the experimental treatment (cycle 1 day 1, n = 202)		OR (90% CI)	P value
	Yes, n (%)	No, n (%)		
<b>Sex</b>				0.822
Female	69 (75.00)	23 (25.00)	1	
Male	84 (76.36)	26 (23.64)	1.08 (0.63-1.85)	
<b>Drugs combination</b>				0.404
No	63 (72.41)	24 (27.59)	1	
Yes	67 (77.91)	19 (22.09)	1.34 (0.75-2.40)	
<b>Number of people at home (including the patient)</b>				0.253
1 people	37 (82.22)	8 (17.78)	1	
≥3 people	116 (73.89)	41 (26.11)	0.61 (0.30-1.24)	
<b>Education level</b>				0.670
<High-school degree	89 (76.72)	27 (23.28)	1	
≥High-school degree	60 (74.07)	21 (25.93)	0.87 (0.50-1.51)	
<b>Initial care received in another hospital without a phase I unit</b>				0.045
No	69 (83.13)	14 (16.87)	1	
Yes	82 (70.69)	34 (29.31)	0.49 (0.27-0.88)	

OR, odds ratio; 90% CI, 90% confidence interval.

Reports from phase I units in cancer centers worldwide have not shown increased toxicity or dose-limiting toxicities with the exception of Schwandt et al., who described an association between age >80 years and the probability of dose-limiting toxicity.<sup>27-37</sup> Therefore enrollment of older patients in early-phase clinical trials should be encouraged by health authorities not only in the United States but also in Europe. Le Saux et al.<sup>38</sup> showed that efforts have been made comparing two periods (2001-2004 and 2011-2014). There was an increase in the number of clinical trials reporting results on older patients, especially dedicated phase I studies and subgroup analyses of phase III studies.<sup>38</sup> However, no trials required an assessment of physiological age at study entry to help physician decision in real life.

In our study, older patients lived closer to the hospital. This is consistent with previous reports. Basche et al.<sup>39</sup> found that traveling to the University Cancer Center was the most frequent barrier to participate in early-phase trials (34% of respondents; 95% CI 29%-38%). In another study conducted as semistructured interviews of community and academic oncologists, one of the most common barriers cited by community oncologists was caregiver burden (12% of participants interviewed), including emotional and logistical barriers that can influence patient willingness to participate.<sup>40</sup> One of the proposals made in an FDA-ASCO workshop was to work with sponsors to open more trials in community settings.<sup>15</sup> However, phase I units usually require specific facilities that may not be available in community centers.

Surprisingly, the sex ratio was in favor of males in older patients and females in younger patients. This might be explained by the different tumor types in each cohort. There were more patients with breast cancer in the younger population and more patients with hematological malignancies in the older population.

Signature of informed consent was similar between the two age categories as well as the rate of screening failure. The proportion of screening failure was consistent with that found in the published literature. In a monocentric retrospective study performed among 773 American patients with cancer included in phase I trials, one-quarter of them were screening failures.<sup>41</sup> Another French case-control monocentric study showed that among 1293 patients enrolled in phase I trials, 15% were screening failures.<sup>42</sup> Our results support the evidence that older patients are not at an increased risk of screening failure and therefore should not be excluded from early-phase clinical trials.

Education level was not associated in univariate analysis with the administration of the experimental treatment in older patients. This is an encouraging result suggesting that level of education did not affect participation in an early clinical trial. This is not consistent with a previous report that showed that patients with lower incomes were less likely to participate in a clinical trial.<sup>43,44</sup> However, this difference might be related to the health care system. Patients with a higher-income in the United States are better insured. In France, patients are entitled to public health insurance regardless of their income. In our study, all patients were seen in the hospital by the phase I team to

discuss the clinical trial. They were already selected by their caring physician to potentially fulfill clinical trial inclusion criteria. Mohd Noor et al.<sup>44</sup> showed in a multivariate analysis that most deprived patients were significantly less likely to be referred for consideration of an early-phase clinical trial [OR 0.53, 95% CI 0.38-0.74;  $P = 0.002$ ]. This difference was lost once referred for consideration (OR 0.81, 95% CI 0.40-1.63;  $P = 0.163$ ). This might explain our results.

Our findings must be interpreted in the light of some limitations. First, the survey was conducted between 2015 and 2016 before the immunotherapy era. One of the main barriers to enrollment stated by older patients is the concerns about moderate or severe toxicity.<sup>39</sup> Immunotherapy is an attractive option in older patients with fewer toxicities than cytotoxic chemotherapies or some targeted therapies and might influence the enrollment in clinical trials.<sup>45</sup> Second, the survey did not include all phase I units in France. However, 11 units agreed to participate out of a total of 16 units in France (68.8%). It would be of particular interest to reiterate the survey a few years later to see potential changes in the enrollment of older patients.

Considering the epidemiological changes and the growing population of older patients with cancer in the future, enrollment of this population remains a major concern.<sup>46</sup> Health authorities should follow the footsteps of the FDA and engage more efforts in the assessment of treatment efficacy and safety in older patients. Along with these measures, some specificities related to older patients should be considered and implemented to increase enrollment in early-phase clinical trials such as dedicated patient care, tailored information, and early involvement of the caregiver.

## Conclusions

Older patients are underrepresented in early clinical trials with 17.7% of patients aged  $\geq 70$  years in our study compared with the number of new cases of cancer in France (50%). However, when invited to participate, older patients were prone to sign informed consent.

## ACKNOWLEDGEMENTS

We acknowledge support by INCa, CLIP<sup>2</sup>, and Unicancer.

## FUNDING

INCa (no grant number).

## DISCLOSURE

The authors have declared no conflicts of interest.

## REFERENCES

1. DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019. *CA Cancer J Clin*. 2019;69(6):452-467.
2. Pilleron S, Soto-Perez-de-Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. *Int J Cancer*. 2021;148(3):601-608.
3. FDA pushes enrollment of older adults in trials. *Cancer Discov*. 2020;10(5):OF1.

4. FDA. Inclusion of Older Adults in Cancer Clinical Trials. Clin Trials: 9. Guidance for Industry. White Oak, MD FDA; March 2020. Available at <https://www.fda.gov/media/135804/download>. Accessed March 30, 2022.
5. Rey G, Jouglé E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. *BMC Public Health*. 2009;9:33.
6. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209-249.
7. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. *Cancer*. 1994;74(suppl 7):2208-2214.
8. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. *J Clin Oncol*. 2003;21(7):1383-1389.
9. Noone A, Howlander N, Krapcho M. *SEER Cancer Statistics Review, 1975-2015*. Bethesda, MD: National Cancer Institute; 2017.
10. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. *JAMA*. 2004;291(22):2720-2726.
11. Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. *JAMA Oncol*. 2019;5(12):1769-1773.
12. Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. *J Clin Oncol*. 2015;33(32):3826-3833.
13. Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. *J Clin Oncol*. 2017;35(33):3745-3752.
14. Abbasi J. Older patients (still) left out of cancer clinical trials. *JAMA*. 2019;322(18):1751-1753.
15. Levit LA, Singh H, Klepin HD, Hurria A. Expanding the evidence base in geriatric oncology: action items from an FDA-ASCO workshop. *J Natl Cancer Inst*. 2018;110(11):1163-1170.
16. Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. *J Clin Oncol*. 2017;35(33):3737-3744.
17. Cerreta F, Eichler H-G, Rasi G. Drug policy for an aging population—the European Medicines Agency's geriatric medicines strategy. *N Engl J Med*. 2012;367(21):1972-1974.
18. European Medicines Agency. Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations. Available at [https://www.ema.europa.eu/en/documents/scientific-guideline/draft-points-to-consider-frailty-evaluation-instruments-baseline-characterisation-clinical-trial\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-points-to-consider-frailty-evaluation-instruments-baseline-characterisation-clinical-trial_en.pdf). Accessed March 30, 2022.
19. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol*. 2014;32(24):2595-2603.
20. Li D, Sun C-L, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. *JAMA Oncol*. 2021;7(11):e214158.
21. Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. *Lancet Lond Engl*. 2021;398(10314):1894-1904.
22. Rostoft S, O'Donovan A, Soubeyran P, Alibhai SMH, Hamaker ME. Geriatric assessment and management in cancer. *J Clin Oncol*. 2021;39(19):2058-2067.
23. Battisti NML, Liposits G, De Glas NA, Gomes F, Baldini C, Mohile S. Systemic therapy of common tumours in older patients: challenges and opportunities. A young international society of geriatric oncology review paper. *Curr Oncol Rep*. 2020;22(10):98.
24. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. *J Clin Oncol*. 2018;36(22):2326-2347.
25. Decoster L, van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. *Ann Oncol*. 2015;26(2):288-300.
26. Paillaud E, Soubeyran P, Caillet P, et al. Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: a French initiative with international survey. *Eur J Cancer Oxf Engl 1990*. 2018;103:61-68.
27. LoConte NK, Smith M, Alberti D, et al. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. *Cancer Chemother Pharmacol*. 2010;65(4):775-780.
28. Rowe J, Patel S, Mazo-Canola M, et al. An evaluation of elderly patients ( $\geq 70$  years old) enrolled in phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011. *J Geriatr Oncol*. 2014;5(1):65-70.
29. Tai WM, Lim C, Ahmad A, et al. Do elderly patients benefit from enrollment into phase I trials? *J Geriatr Oncol*. 2015;6(3):241-248.
30. Mahipal A, Denson AC, Djulbegovic B, et al. Effect of age on clinical outcomes in phase I trial participants. *Cancer Control*. 2015;22(2):235-241.
31. Helissey C, Biondani P, Roquet F, et al. Patients aged over 75 years enrolled in phase I clinical trials: the Gustave Roussy experience. *Int J Cancer*. 2016;138(4):875-880.
32. Subbiah IM, Wheler JJ, Hess KR, et al. Outcomes of patients  $\geq 65$  years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. *Int J Cancer*. 2017;140(1):208-215.
33. Zafar SF, Heilbrun LK, Vishnu P, et al. Participation and survival of geriatric patients in phase I clinical trials: the Karmanos Cancer Institute (KCI) experience. *J Geriatr Oncol*. 2011;2(1):18-24.
34. Gaddipati H, Fu P, Dowlati A. Phase I clinical trials in patients  $\geq 80$ . *J Geriatr Oncol*. 2011;2(2):142-146.
35. Khan KH, Yap TA, Ring A, et al. Phase I trial outcomes in older patients with advanced solid tumours. *Br J Cancer*. 2016;114(3):262-268.
36. Schwandt A, Harris PJ, Hunsberger S, et al. The role of age on dose-limiting toxicities in phase I dose-escalation trials. *Clin Cancer Res*. 2014;20(18):4768-4775.
37. Baldini C, Le Saux O, Helissey C, et al. Are phase I trials safe for older patients? *J Geriatr Oncol*. 2018;9(2):87-92.
38. Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Inclusion of elderly patients in oncology clinical trials. *Ann Oncol*. 2016;27(9):1799-1804.
39. Basche M, Barón AE, Eckhardt SG, et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. *J Oncol Pract*. 2008;4(4):162-168.
40. Sedrak MS, Mohile SG, Sun V, et al. Barriers to clinical trial enrollment of older adults with cancer: a qualitative study of the perceptions of community and academic oncologists. *J Geriatr Oncol*. 2020;11(2):327-334.
41. Mckane A, Sima C, Ramanathan RK, et al. Determinants of patient screen failures in phase I clinical trials. *Invest New Drugs*. 2013;31(3):774-779.
42. Kempf E, Lemoine N, Tergemina-Clain G, et al. A case-control study brings to light the causes of screen failures in phase I cancer clinical trials. *PLoS One*. 2016;11(5):e0154895.
43. Unger JM, Hershman DL, Albain KS, et al. Patient income level and cancer clinical trial participation. *J Clin Oncol*. 2013;31(5):536-542.
44. Mohd Noor A, Sarker D, Vizor S, et al. Effect of patient socioeconomic status on access to early-phase cancer trials. *J Clin Oncol*. 2013;31(2):224-230.
45. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373(17):1627-1639.
46. Kendal WS. Dying with cancer: the influence of age, comorbidity, and cancer site. *Cancer*. 2008;112(6):1354-1362.